Company: ENTXW
Filing Date: 2025-06-05
Form Type: DEF 14A
Source: 0001178913-25-002111
Chunk: 47

Company: Entera Bio Ltd.
Filing Date: 2025-06-05
Form: DEF 14A
Chunk 47
---
 discussed in Note 6 of the Company’s audited financial statements for the year ended December 31, 2024 included in the 2024 Annual Report. The fair value amount is recognized as 
 an expense over the course of the vesting period of the options (subject to any applicable accounting adjustments during that period).                                                                                                           |

| (2) | Reflects the associated annual expenses for fully vested Ordinary Shares granted in lieu of cash fees during 2024, based on the grant date market value. |

| (3) | Former board member whose term expired at the 2024 Annual Meeting of Shareholders. |

The table below sets forth the aggregate number of options to purchase Ordinary Shares of each current non-employee director outstanding as of December 31, 2024: Entera Bio Ltd. | 2025 Annual Meeting Proxy Statement 28

| Name             |     | Share Options |         |
| Gerald Lieberman |     |               | 374,421 |
| Yonatan Malca    |     |               | 374,421 |
| Gerald M. Ostrov |     |               | 374,421 |
| Sean Ellis       |     |               | 374,421 |
| Haya Taitel      |     |               | 141,971 |

Employment Agreements We have entered into employment agreements with our Named Executive Officers. A summary of the material terms of these agreements with each of our Named Executive Officers is set forth below. The below descriptions of employment agreements and separation agreements, as applicable, are only summaries and are qualified in their entirety by reference to the full text of the applicable agreement, which are filed as exhibits to our 2024 Annual Report on Form 10-K. Miranda Toledano Ms. Toledano has served on the Board of Directors at Entera since September 2018. Between May and July 2022, Ms. Toledano served as Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy at Entera. In July 2022, Ms. Toledano was appointed Chief Executive Officer at Entera. In connection with Ms. Toledano’s appointment asChief Business Officer, Chief Financial Officer and Head of Corporate Strategy in May 2022, Ms. Toledano entered into an employment agreement (the “Original Employment Agreement”) with the Company, providing for an annual employer cost of $350,000 inclusive of base salary, pension payments, severance and disability benefits as required under Israeli law. Additionally, Ms.